Nicholas Hoffman & Company LLC. grew its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 14.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 948 shares of the medical research company’s stock after purchasing an additional 118 shares during the quarter. Nicholas Hoffman & Company LLC.’s holdings in Amgen were worth $231,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also made changes to their positions in the company. Regency Capital Management Inc. DE acquired a new stake in Amgen during the 1st quarter worth $27,000. Maverick Capital Ltd. acquired a new stake in Amgen during the 1st quarter worth $27,000. Elmwood Wealth Management Inc. acquired a new stake in Amgen during the 1st quarter worth $31,000. Wolverine Asset Management LLC boosted its stake in Amgen by 1,587.5% during the 1st quarter. Wolverine Asset Management LLC now owns 135 shares of the medical research company’s stock worth $33,000 after purchasing an additional 127 shares during the last quarter. Finally, KB Financial Partners LLC acquired a new stake in Amgen during the 1st quarter worth $35,000. 74.73% of the stock is currently owned by institutional investors.
Shares of NASDAQ:AMGN opened at $216.04 on Wednesday. The company has a debt-to-equity ratio of 3.45, a current ratio of 1.31 and a quick ratio of 1.03. The firm has a market capitalization of $122.68 billion, a PE ratio of 21.98, a price-to-earnings-growth ratio of 1.55 and a beta of 0.68. The firm’s 50-day moving average is $232.74 and its two-hundred day moving average is $240.06. Amgen Inc. has a 1 year low of $210.28 and a 1 year high of $276.69.
The firm also recently declared a quarterly dividend, which was paid on Wednesday, September 8th. Shareholders of record on Tuesday, August 17th were paid a dividend of $1.76 per share. The ex-dividend date of this dividend was Monday, August 16th. This represents a $7.04 dividend on an annualized basis and a yield of 3.26%. Amgen’s dividend payout ratio (DPR) is presently 42.41%.
AMGN has been the topic of several recent research reports. Zacks Investment Research raised shares of Amgen from a “sell” rating to a “hold” rating and set a $255.00 target price on the stock in a research note on Tuesday, June 29th. SVB Leerink lowered their price target on shares of Amgen from $238.00 to $234.00 and set a “market perform” rating on the stock in a research report on Wednesday, August 4th. Robert W. Baird reissued a “sell” rating on shares of Amgen in a research report on Thursday, August 5th. Oppenheimer boosted their price target on shares of Amgen from $272.00 to $277.00 and gave the company an “outperform” rating in a research report on Monday, June 7th. Finally, Mizuho initiated coverage on shares of Amgen in a research report on Friday, September 10th. They set a “hold” rating and a $222.00 price target on the stock. Two analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $249.70.
Amgen, Inc is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA.
Read More: What is the Gross Domestic Product (GDP)?
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.